Drug Profile
Ceramide nanoliposomal - PendreaBio
Alternative Names: Ceramide NanoLiposome; Ceraxa; CNL; KN 001; KN-001 - PendreaBio; KN-01; Nanoliposomal ceramideLatest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Keystone Nano
- Developer PendreaBio; University of Virginia
- Class Antineoplastics; Ceramides; Neuroprotectants; Sphingolipids
- Mechanism of Action Undecaprenyl pyrophosphate synthetase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- Phase I/II Solid tumours
- Preclinical Prostate cancer
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA (Liposomal)
- 21 Jan 2021 Keystone Nano plans a phase I trial for Acute Myeloid Leukemia (Second-line therapy or greater) in USA in February 2021 (NCT04716452; KNAN2001 )
- 22 Jun 2020 Pharmacodynamics data from a preclinical study in Prostate cancer presented at the 111th Annual Meeting of the American Association for Cancer Research - II (AACR-2020)